SMNR (Semnur Pharmaceuticals) Total Liabilities: $27.30 Mil (As of Mar. 2026)


SMNR Semnur Pharmaceuticals Inc SMNR
8 GF Score
Price $0.68
View Full Analysis

What is Semnur Pharmaceuticals Total Liabilities?

Semnur Pharmaceuticals SMNR +4.62% 8 Total Liabilities is $27.30 Mil as of Mar. 2026. GuruFocus rates SMNR with a GF Score™ of 8/100.

Semnur Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2026 was $27.30 Mil.

Semnur Pharmaceuticals's quarterly Total Liabilities increased from Sep. 2025 ($15.37 Mil) to Dec. 2025 ($22.10 Mil) and increased from Dec. 2025 ($22.10 Mil) to Mar. 2026 ($27.30 Mil).

Semnur Pharmaceuticals's annual Total Liabilities increased from Dec. 2023 ($38.80 Mil) to Dec. 2024 ($49.47 Mil) but then declined from Dec. 2024 ($49.47 Mil) to Dec. 2025 ($22.10 Mil).

Semnur Pharmaceuticals Total Liabilities Historical Data

* Premium members only.

The historical data trend for Semnur Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Semnur Pharmaceuticals Total Liabilities Chart

Semnur Pharmaceuticals Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Liabilities
35.60 38.80 49.47 22.10

Semnur Pharmaceuticals Quarterly Data
Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 50.96 53.53 15.37 22.10 27.30
SMNR
8GF Score
Semnur Pharmaceuticals Inc SMNR
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Semnur Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Semnur Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=10.168+(11.928+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=22.10

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=1.346--20.75
=22.10

Semnur Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=10.38+(16.915+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=27.30

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=1.969--25.326
=27.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $27.30 Mil mean?
Semnur Pharmaceuticals (SMNR) has a Total Liabilities of $27.30 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Semnur Pharmaceuticals and its competitors.
Is Semnur Pharmaceuticals' Total Liabilities too high?
Semnur Pharmaceuticals' current Total Liabilities is $27.30 Mil. Overall, Semnur Pharmaceuticals has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Semnur Pharmaceuticals' Total Liabilities compare to CNTB and ENLV?
Semnur Pharmaceuticals' Total Liabilities of $27.30 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Semnur Pharmaceuticals and its competitors. Semnur Pharmaceuticals's current Total Liabilities is $27.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Semnur Pharmaceuticals stock overvalued right now?
Semnur Pharmaceuticals (SMNR) has a current Total Liabilities of $27.30 Mil. The current Total Liabilities is $27.30 Mil. Semnur Pharmaceuticals' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Semnur Pharmaceuticals (SMNR), the current Total Liabilities is $27.30 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Semnur Pharmaceuticals Business Description

Address 960 San Antonio Road, Palo Alto, CA, USA, 94303
Semnur Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its main product candidate, SP-102 (10 mg, dexamethasone sodium phosphate viscous gel), is being developed as a non-opioid novel injectable corticosteroid gel formulation for patients with moderate to severe LRP (also known as sciatica), containing no preservatives, surfactants, solvents, or particulates.
8GF Score

Get the complete analysis for SMNR

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.68
Price